Vasoactive Peptide Levels after Change of Dialysis Mode

Fredrik Uhlin a, b, f Ingegerd Odar-Cederlöf e Elvar Theodorsson c, d
Anders Fernström a, b

Departments of a Nephrology, Region Östergötland, and b Medical and Health Sciences, Linköping University, c Division of Microbiology and Molecular Medicine, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, and d Department of Clinical Chemistry, Center for Diagnostics, County Council of Östergötland, Linköping, and e Department of Clinical Pharmacology, Karolinska University Hospital Huddinge, Stockholm, Sweden; f Department of Biomedical Engineering, Technomedicum, Tallinn University of Technology, Tallinn, Estonia

Key Words
Vasoactive peptides · N-terminal fragment of pro-brain natriuretic peptide · Neuropeptide Y · Convective therapies · Hemodiafiltration

Abstract
Background/Aims: Plasma concentrations of the N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) are increased in end-stage renal disease. Improvement in hemodynamic stability has been reported when switching from hemodialysis (HD) to on-line hemodiafiltration (ol-HDF). The aim of this study was to investigate plasma concentrations of NT-proBNP, BNP and neuropeptide Y (NPY) during a 1-year follow-up, after a change from high-flux HD to postdilution ol-HDF. Additional variables were also studied, e.g. pulse wave velocity and ordinary clinical parameters. Method: We conducted a prospective, single-center study including 35 patients who were switched from HD to HDF. Plasma concentrations of NT-proBNP, BNP and NPY before and after dialysis were measured at baseline (i.e. HD) and at 1, 2, 4, 6 and 12 months on HDF. Results: All three peptide levels decreased significantly during HD and HDF when comparing concentrations before and after dialysis. Mean absolute value (before/after) and relative decrease (%) before versus after dialysis was 13.697/9.497 ng/l (31%) for NT-proBNP, 62/40 ng/ml (35%) for BNP and 664/364 pg/l (45%) for NPY. No significant differences were observed when comparing predialysis values over time. However, postdialysis NT-proBNP concentration showed a significant decrease of 48% over time after the switch to HDF. Conclusion: The postdialysis plasma levels of NT-proBNP, BNP and NPY de-
creased significantly during both dialysis modes when compared to before dialysis. The post-
dialysis lowering of NT-proBNP increased further over time after the switch to ol-HDF; the
predialysis levels were unchanged, suggesting no effect on its production in the ventricles of
the heart.

**Introduction**

Brain natriuretic peptide, or B-type natriuretic peptide (BNP), participates in the regu-
lation of cardiovascular function. It is mainly produced in the ventricular myocytes, and the
proBNP is cleaved into BNP_{32} and N-terminal fragment (NT)-proBNP_{1–76}, which are both
released into the blood stream with a half-life of 20 and 120 min, respectively [1]. BNP is
active as a vasodilator and contributes to the relaxation of the myocardium. Plasma levels of
BNP rise with decreasing left ventricular function and are used as biomarkers of heart failure.
NT-proBNP likewise increases and has partly replaced BNP as a rapid diagnostic due to its
stability and convenient determination. NT-proBNP is an important marker of left ventricular
dysfunction, and the concentrations correlate with the left ventricular mass index and left
auricular diameter [2]. NT-proBNP is therefore a potential marker for left ventricular remod-
eling, a common finding in patients with end-stage renal disease (ESRD). NT-proBNP seems
to have an even greater prognostic value in patients with ESRD compared to other established
cardiac biomarkers, e.g. troponin T (TnT) [3], even in asymptomatic hemodialysis (HD) pa-
tients [4]. NT-proBNP concentration is altered in ESRD patients, and increasing values are a
risk factor for cardiovascular events and mortality in HD patients with type 2 diabetes mellitus
[5] and HD patients in general [6]. In a recent study, an association of changes in NT-proBNP
longitudinally with changes in inflammation, nutritional status, age and comorbidity was
observed [7]. NT-proBNP has also been reported to be a predictor of early mortality (<1 year)
in the dialysis population, even if the high-sensitivity TnT seems to be a better predictor for
later mortality [8]. A significant decrease in BNP levels has been reported when changing HD
frequency from 3 times per week to daily [9], and also NT-proBNP in some patients [10]. No
difference was seen when comparing HD patients with peritoneal dialysis patients [11].

Neuropeptide Y (NPY) is a 36-amino acid polypeptide neurotransmitter found in the
sympathetic nervous system and in the central nervous system. NPY exerts a role in various
physiological functions, including the regulation of blood pressure, circadian rhythm, feeding
behavior, anxiety, memory processing and cognition [12–14]. Plasma NPY is co-released with
noradrenaline in response to sympathetic nervous stimulation and modulates the action of
noradrenaline. NPY is also present in the heart and contributes to cardiovascular remodeling
[15].

There has been a re-awakened interest in convective dialysis modalities since a new tech-
nology in dialysis machines and water purification has been implemented in dialysis units,
especially in postdilution on-line hemodiafiltration (ol-HDF). Recently, a large randomized
controlled study showed a lower risk of all-cause mortality, cardiovascular mortality and
infection-related mortality in patients assigned to postdilution ol-HDF compared with pa-
tients on high-flux HD [16].

Frequent dialysis treatments improve markers of heart failure in the dialysis population
[9, 17], but could a similar improvement be detected by increasing the efficiency of uremic
toxins/middle-molecule removal by switching over to a convensional dialysis method such as
ol-HDF? The aim of this study was to evaluate a 1-year follow-up in patients changing from
HD to ol-HDF with respect to the levels of vasoactive peptides NT-proBNP, BNP and NPY.
**Materials and Methods**

**Study Subjects and Design**

Thirty-five patients on chronic HD from the Department of Nephrology, University Hospital, Linköping, Sweden, were included in the study. Figure 1 shows the patient flow through the study. The exclusion criteria were: patients that did not accept informed consent, did not understand the Swedish language, had a dysfunctional blood access and patients that were clearly in a palliative condition, i.e. dialysis time had been reduced and death was supposed to occur within a few weeks. This means that patients with serious heart failure were also included, as were patients with several other comorbidities (such as diabetes and
malignancy). The dialysis monitor used in all treatments was Fresenius 5008 (Fresenius Medical Care, Germany); the dialyzers used during HD (baseline) were FX 80, and during the ol-HDF period (12 months) FX 800 (Fresenius Medical Care), both with an effective membrane area of 1.8 m² and an ultrafiltration (UF) coefficient of 59 and 63 ml/h mm Hg, respectively. Both dialyzers had the same permeability for the middle molecule representative β₂-microglobulin, a sieving coefficient of 0.8. The duration of the treatments varied between 180 and 270 min, the dialysate flow was 500 ml/min and the blood flow varied between 280 and 350 ml/min. The AutoSub system mode for calculation of the on-line prepared convection fluid volume (Vc) by the dialysis machine was used during all ol-HDF treatments, enabling automatic calculations based on parameters such as patients’ total protein and hematocrit values. The Vc during the ol-HDF sessions varied between 10.1 and 28.3 liters per session (mean ± SD 20.3 ± 4.2 liters). Table 1 shows the characteristics of the included patients at baseline. A few sub-analyses (in the case of NT-proBNP) were also performed dividing data into a subset of patients: with or without a history of cardiovascular disease (CVD) and having diabetes or not.

### Table 1. Baseline characteristics of the 35 patients

| Characteristic                                      | Mean ± SD   | n  |
|-----------------------------------------------------|-------------|----|
| Duration of dialysis, months                        | 46.9 ± 53.9 | 35 |
| BMI                                                 | 25.5 ± 4.2  | 35 |
| Predialysis systolic blood pressure, mm Hg          | 147.4 ± 29.0| 35 |
| Predialysis diastolic blood pressure, mm Hg         | 64.6 ± 12.4 | 35 |
| Dialysis time/week, h                               | 11.6 ± 2.5  | 35 |
| Males/females                                       | 30/5        |    |
| Age, years                                          | 70.8 ± 12.5 | 35 |
| Comorbidity (other diagnoses)                       | 27          |    |
| Malignancy                                          | 10          |    |
| Pulmonary disease                                   | 4           |    |
| Endocrine disease                                   | 1           |    |
| Metabolic disease                                   | 1           |    |
| Gastrointestinal disease                            | 3           |    |
| Neurological disease                                | 2           |    |
| Rheumatoid arthritis                                | 2           |    |
| Diabetes mellitus (type 1, n = 5/type 2, n = 7)     | 12          |    |
| History of cardiovascular disease                   | 24          |    |
| Medication                                          |             |    |
| Vitamin D (alfacalcidol and/or paricalcitol)        | 32          |    |
| Phosphate binders (lantan or sevelamer)             | 18          |    |
| Calcium (calcium carbonate)                         | 29          |    |
| Calcimimetics (cinacalcet)                          | 5           |    |
| Antihypertensives (felodipin, enalapril, metoprolol, amlodipin, losartan, doxazocin, isosorbide mononitrate, irbesartan) | 31          |    |

**Sampling Procedure**

All samples from a total of 196 observed dialysis treatments were collected at the midweek session. Predialysis blood samples were collected after a 10-min rest in the lying position and postdialysis samples immediately after end of the same session still in the lying position. Immediately after the samples were collected, the test tubes were turned upside down 8–10 times and immediately placed on a wet ice bath. Within 60 min, the samples were centrifuged for 10 min at 2,000 rpm, and plasma was separated into 1.25-ml Cryotubes and placed in a freezer at a temperature below −70°C.
To validate, baseline samples were collected twice at the baseline period (i.e. the patient was treated with HD) at an interval of 1–2 weeks (B1 and B2). During the follow-up study period, samples were collected at 1, 2, 4, 6 and 12 months from the start of ol-HDF.

Measurements of the concentrations of NT-proBNP in plasma were performed using Cobas e 602 from Roche Diagnostics, and reagents from Roche (http://www.cobas.com). The total imprecision (% coefficient of variation) during 5 months of use was 3.8% at mean concentrations of 196 ng/l and 4.8% at 2,140 ng/l. Several patients had concentrations above the upper limit of the instrumentation, 35,000 ng/l. In those cases, a reanalysis was performed using a diluting buffer provided by Roche Diagnostics. Plasma samples were extracted using Sep-Pak® Plus C18 reverse-phase cartridges (Waters, Milford, Mass., USA) before measuring the concentrations of BNP-32 and NPY. BNP-32 was measured using BNP-32 Human Fluorescent EIA kit (Nordic BioSite AB, Täby, Sweden). The lowest detectable concentration was 15.8 pg/ml, intra-assay coefficient of variation <10% and inter-assay coefficient of variation <15%. The concentrations of human NPY were measured using an in-house radioimmunoassay based on a rabbit antiserum NPY2151 (IC50 = 24 pmol/l) raised against BSA-conjugated human NPY. 125I-labeled and reverse-phase HPLC purified human NPY was used as radioligand and human NPY as calibrator. The lowest detectable concentration was 4 pmol/l. Intra- and interassay coefficients of variation were 6 and 11%, respectively. Samples were lacking from 3 patients; 1 got transplanted during the baseline period and 2 were found to be hepatitis C positive (not accepted at the laboratory).

Pulse Wave Velocity

Blood vessel elasticity was estimated using a tonometer (SphygmoCor®; AtCor Medical, Australia) to obtain a measure of the patients’ general (aortic) vascular status. The measurements were performed, with connected ECG, by recording the pulse of the femoral and carotid artery on the opposite side.

Statistical Analyses

In some patients, the concentration values of NT-proBNP were extremely high (lowest 149.0 and highest 219,897.0 ng/l), yielding highly skewed data. Also highly skewed data were observed in BNP (lowest 0.004 and highest 1,306.9 ng/ml) and in NPY (lowest 2.0 and highest 2,932.9 pmol/l). Data were therefore logarithmically transformed (log10) before analysis. No data were excluded. To validate the baseline, a comparison between values at baseline 1 (B1) and at baseline 2 (B2) using Student’s t test was performed, showing no significant difference, p > 0.05. In cases where a comparison was made between two groups, Student’s t test was used at the same p level as above. To investigate if there was a difference in mean concentration of peptides in plasma over the study period, ANOVA (repeated measure) was used and a p value <0.05 was considered as significant. Correlations between UF volume, systolic and diastolic blood pressure, pulse wave velocity (PWV), routine laboratory parameters, and the vasoactive peptides were also performed (Pearson correlation coefficient). The Regional Ethical Review Board approved (Dnr M153–07) the study protocol, and written informed consent was obtained from all patients.

Results

Figure 1 shows the number of included prevalent patients and dropouts during the study period. Of the total number of 61 available patients at our in-hospital dialysis unit, 26 did not meet the inclusion criteria, i.e. did not understand Swedish (n = 11), did not accept informed
consent (n = 7), had too low access flow for ol-HDF (n = 4), were psychotic or had senile dementia (n = 3) or terminal condition (n = 1). The mortality rate was approximately 8.6% for the first 6 months and 25.7% for the whole year. All 9 patients who died during the study period had a history of serious cardiovascular incidents, and the cause of death was stroke (n = 2), acute myocardial infarction (n = 2), cardiac arrest (n = 2), ischemic leg resulting in amputation followed by infection (n = 2) and heart failure with septicemia (n = 1). As an example of early mortality, a few extreme values were observed, especially in the case of NT-proBNP, during the sampling period of 2 months, e.g. 1 patient had an analgesic pump with morphine for his severe angina pectoris and exhibited predialysis and postdialysis NT-proBNP values of 219.897 and 193.261 ng/l, respectively. This patient died a few days after that sampling. During the sampling period of 6 months, 1 patient had a pre- and postdialysis value of 171.067 and 173.233 ng/l, respectively; this patient suffered from a cerebral stroke a few days later and died after some days.

Table 2 presents additional data (routine laboratory data and PWV) of the patients from baseline (HD) and from 6 to 12 months of ol-HDF treatment. Statistically significant differences compared to baseline are highlighted in the table. The reduction ratio (RR) for β2-microglobulin represents the most obvious change.

Figure 2 shows the patients’ individual predialysis plasma values before and after the switch to ol-HDF for the 3 peptides, where HD is the mean of the two baseline predialysis values (B1, B2) and ol-HDF is the mean of the 5 follow-up predialysis values (1, 2, 4, 6 and 12 months) for each patient. No difference in predialysis values was found between HD and ol-HDF (p > 0.05).

Figure 3 presents the mean of the pre- and postdialysis values at group level; figure 3a for NT-proBNP, figure 3b for BNP and figure 3c for NPY. The postdialysis plasma values decreased significantly for all peptides when compared to predialysis (p < 0.05). Mean absolute values (before/after) and relative decrease before versus after dialysis was 13.697/9.497 ng/l (31%) for NT-proBNP, 62/40 ng/ml (35%) for BNP and 664/364 pg/l (45%) for NPY. The postdialysis NT-proBNP decreased significantly during the ol-HDF period (p < 0.0001), showing a mean value at baseline of 11.004 ng/l and 5.760 ng/l (48%) at 12

| Table 2. Additional patient data during the study period |
|----------------------------------------------------------|
| **Baseline** | **6 months** | **12 months** | **p** |
|--------------|-------------|--------------|------|
| **mean ± SD** | **mean ± SD** | **mean ± SD** | **n** | **n** | **n** |
| **Hemoglobin, g/l** | 125.8 ± 13.4 | 124.5 ± 15.0 | 120.0 ± 15.0* | 35 | 31 | 24 | 0.04 |
| Parathyroid hormone, ng/l | 293.9 ± 227.2 | 289.3 ± 251.2 | 361.2 ± 376.9 | 35 | 31 | 24 | 0.41 |
| Ionized calcium, mmol/l | 1.2 ± 0.1 | 1.2 ± 0.1 | 1.2 ± 0.1 | 34 | 30 | 24 | 0.26 |
| Phosphorus, mmol/l | 1.8 ± 0.7 | 1.6 ± 0.4 | 1.5 ± 0.5* | 35 | 31 | 24 | 0.04 |
| Albumin, g/l | 35.0 ± 4.6 | 35.4 ± 5.4 | 35.6 ± 4.3 | 35 | 31 | 24 | 0.88 |
| CRP, mg/l | 25.6 ± 40.3 | 26.1 ± 29.8 | 13.4 ± 6.1 | 35 | 31 | 24 | 0.33 |
| Predialysis systolic blood pressure, mm Hg | 142.4 ± 29.0 | 152.8 ± 34.4 | 148.7 ± 27.5 | 35 | 31 | 24 | 0.28 |
| Predialysis diastolic blood pressure, mm Hg | 64.6 ± 12.4 | 68.8 ± 17.6 | 68.9 ± 15.5 | 35 | 31 | 24 | 0.64 |
| Dialysis time/week, h | 11.6 ± 2.5 | 12.1 ± 2.6 | 11.9 ± 3.6 | 35 | 31 | 24 | 0.56 |
| Predialysis urea, mmol/l | 20.2 ± 4.9 | 17.9 ± 3.8* | 16.9 ± 4.3* | 35 | 31 | 24 | 0.03 |
| Kt/V, single pool | 1.4 ± 0.2 | 1.5 ± 0.4 | 1.4 ± 0.3 | 34 | 30 | 24 | 0.14 |
| URR, % | 68.8 ± 6.4 | 71.8 ± 7.9 | 71.4 ± 7.4 | 35 | 31 | 24 | 0.08 |
| Predialysis β2-microglobulin, mg/l | 24.9 ± 7.3 | 22.3 ± 7.3* | 23.6 ± 6.3 | 33 | 29 | 24 | 0.022 |
| β2-Microglobulin RR, % | 56.4 ± 8.0 | 73.4 ± 8.8* | 73.2 ± 7.6* | 31 | 29 | 24 | <0.0001 |
| PWV, m/s | 12.2 ± 6.0 | 11.7 ± 5.0 | 12.3 ± 4.6 | 26 | 13 | 15 | 0.92 |

**URR = Urea reduction rate. * Significant vs. baseline (t test).**
months but remained unchanged for the other peptides (p > 0.05). In the case of predialysis values, no significant difference was observed over the 12-month period (p > 0.05).

Figure 4 shows the material when divided into subgroups of mean NT-proBNP; an overall lower NT-proBNP was seen in patients without a history of CVD (fig. 4a) and in patients without diabetes (fig. 4c) compared to the patients with a history of CVD (fig. 4b; p = 0.001) and diabetes (fig. 4d; p = 0.01). The picture is similar in the 4 subgroups as seen for the whole material, a greater reduction of postdialysis values during ol-HDF (1, 2, 4, 6 and 12 months) compared to HD (B1 and B2). It was noted that in the group of 9 patients without a history of
CVD (fig. 4a), none died during the 12 months of follow-up. This group also had much lower NT-proBNP values compared to the others; the mean of 63 predialysis NT-proBNP values was 4.549 ng/l compared to 18.120 ng/l for the CVD group (a mean of 133 predialysis values; p = 0.001).

Figure 5 presents scatterplots of predialysis concentration values of NT-proBNP versus BNP and NT-proBNP versus NPY in all studied sessions (n = 196). A significant correlation (p < 0.05) between NT-proBNP and BNP was seen (r = 0.59). No correlation between peptide concentrations and the other included routine clinical parameters and PWV (listed in table 2) was found (p > 0.05).
Discussion

Plasma concentration (before vs. after dialysis) of the vasoactive peptides NT-proBNP, BNP and NPY decreased significantly during both high-flux HD and ol-HDF possibly due to unloading of the heart and elimination of the peptides during dialysis. The predialysis concentrations did not change significantly over time after switching over from HD to ol-HDF (fig. 2, 3), but the postdialysis NT-proBNP decreased significantly for ol-HDF and additionally showed a trend to decrease more over time (fig. 3a), which may be a result of a larger elimination compared to HD and/or due to the fact that patients with severe heart disease died early in the study. The molecular size of NT-proBNP is 8.5 kDa [18] (BNP 3.5 and NPY 4.3 kDa), which is lower than the cutoff for the dialyzers that were used, e.g. both dialyzers in the present study (FX80 and FX800) have a sieving coefficient of 0.8 for β₂-microglobulin (molecule size 12 kDa). Earlier, Wahl et al. [18] have shown that natriuretic peptides such as NT-proBNP are eliminated during HD since this peptide has also been quantified in spent dialysate. A recently published study by Laveborn et al. [19] also demonstrates a significant decrease (before vs. after dialysis) in NT-proBNP and TnT with high-flux membranes, but
slightly the opposite levels with low-flux membranes. Due to the nonsignificant reduction of the predialysis plasma peptides and the equal sieving coefficients of the dialyzers used, it could be assumed that the convective effect is the main cause of the results in this study and not a considerable improvement in cardiac function. Plasma BNP and NT-proBNP reflect hemodynamic myocardial stress independent of the underlying pathology [1]. Most dialysis patients have an increased ventricular wall stress due to fluid volume and pressure overload on the heart, and their severity and prognosis can be estimated with NT-proBNP and BNP concentrations. Plasma NPY concentrations may increase with fluid and pressure overload, but this seems unlikely in the present study since there was no correlation between NT-proBNP and NPY concentrations (fig. 5b). The stress of the cardiovascular system was not markedly reduced with convective therapy, as reflected by predialysis vasoactive peptide concentrations in this study. Other studies of more frequent treatment have demonstrated a repeal of dialysis-induced myocardial stunning which was attributed to frequent HD due to alteration of UF volume and UF rate [9, 17]. The UF volumes during the observed 196 dialysis sessions in the present study were, in mean ± SD, 1.75 ± 0.88 liters, which is a reasonably ‘normal’ UF volume (approx. fluid overload), and no correlation was found between NT-proBNP and either UF volume or blood pressure. However, postdialysis NT-proBNP values have been found to correlate with volume status in HD patients, especially in those without a history of cardiac disease or hypertension, and may be a guide for determination of target weight for HD patients [20]. In contrast to our 12-month study, a
survival study by Sivalingam et al. [21] showed that patients on HDF had significantly lower levels of both BNP and NT-proBNP compared to patients receiving high-flux HD during a 4-year follow-up. In contrast, in a recent randomized study of cardiovascular parameters, no improvement of arterial stiffness in PWV (m/s) was seen in patients on ol-HDF [22], which is in line with our PWV results (table 2). Of the 9 patients who died during the study period, all but 1 had a history of CVD and higher NT-proBNP. This is consistent with previous studies where NT-proBNP has been reported to be a good predictor of early mortality (<1 year) in the dialysis population [8]. In another recent study, only NT-proBNP was found to be a strong predictor for overall mortality in asymptomatic HD patients and did not improve the prediction of all-cause mortality when combined with high-sensitivity cardiac TnT [23]. As expected, the RR of β2-microglobulin increased significantly after the switch, but the predialysis values of β2-microglobulin were in the same order independent of dialysis mode (table 2). A Vc of >21.95 liters has been reported to be advantageous for reducing mortality [24], and in this study, the mean Vc was 20.3 liters but with a wide distribution from 10.1 to 28.3 liters. An increase in ol-HDF frequency and/or higher Vc are two possible ways to improve the uremic and fluid-overloaded milieu for this patient group. Perhaps an early or immediate start of ol-HDF will reduce some of the long-term negative effects for dialysis patients, thus resulting in better survival.

Future studies, preferably randomized, on a larger number of patients and during a longer follow-up period treated with high-volume ol-HDF are needed in order to clinically confirm beneficial effects with a lowering (and/or an increased elimination) of levels of vasoactive peptides in general, as shown by lower levels of cardiovasoactive peptides.

**Limitations**

The limitations to this study included small sample size, no comparator/randomization, no data concerning residual renal function and additional cardiac parameters.

**Conclusion**

Predialysis peptide concentrations, which most likely have a clinical importance, were not altered for any of the vasoactive peptides (NT-proBNP, BNP and NPY) when switching from high-flux HD to ol-HDF, suggesting no effect on its production in the ventricles of the heart. However, the concentration of NT-proBNP decreased significantly after dialysis following the switch to ol-HDF, assuming there was a larger elimination when compared to HD and/or that a significant number of patients with severe heart disease died early in the study.

**Acknowledgements**

The authors wish to thank all dialysis patients who participated in this study and Micael Gylling, RN, for assistance during measurements. The Linköping University Hospital Research Fund (County Council of Östergötland and Linköping University) and Signhild Engkvists Stiftelse in Stockholm supported analysis costs in this study.

**Disclosure Statement**

The authors have no conflicts of interest to declare.
References

1. Weber M, Hamm C: Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92:843–849.

2. Bargnoux AS, Klouche K, Fareh J, Barazer I, Villard-Saussine S, Dupuy AM, Leray-Moragues H, Giuliani I, Canaud B, Cristol JP: Prohormone brain natriuretic peptide (proBNP), BNP and N-terminal-proBNP circulating levels in chronic hemodialysis patients. Clin Chem Lab Med 2008;46:1019–1024.

3. Hickman PE, McGill DA, Talaulikar G, Hirenmagar B, Bromley J, Rahman A, Koerbin G, Southcott E, Potter JM: Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. Intern Med J 2009;39:812–818.

4. Satyan S, Light RP, Agarwal R: Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007; 50:1009–1019.

5. Winkler K, Wanner C, Drechsler C, Lilienthal J, März W, Krane V; German Diabetes and Dialysis Study Investigators: Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 2008;29:2092–2099.

6. Masden LH, Ladefogd S, Corell P, Schou M, Hildebrandt PR, Atar D: N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007; 71:548–554.

7. Snaedal S, Qureshi AR, Carrero JJ, Heimbürger O, Stenvinkel P, Bárány P: Determinants of N-terminal pro-B-type natriuretic peptide variation in hemodialysis patients and prediction of survival. Blood Purif 2014; 37:138–145.

8. McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE: Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. Clin Chim Acta 2014; 411:936–939.

9. Odar-Cederlöf I, Bjellerup P, Williams A, Blagg CR, Twardowski Z, Ting G, Kjellstrand CM: Daily dialyses decrease plasma levels of brain natriuretic peptide (BNP), a biomarker of left ventricular dysfunction. Hemodial Int 2006;10:394–398.

10. Odar-Cederlöf I, Fehrman I, Bjellerup P, Young B, Blagg C, Kjellstrand CM: Brain natriuretic peptides (BNP) markers of left ventricular dysfunction (LVD) in regular (RHD) and daily hemodialysis (DHD); in 28th Annu Dial Conf, Orlando, March 2008.

11. Sahinarslan A, Güz G, Mutluay R, Okyay K, Demirtaş C, Paşaoğlu H, Yalçın R: The impact of dialysis type on biomarkers for cardiovascular diseases. Turk Kardiyol Dern Ars 2011; 39:456–462.

12. Gray WP: Neuropeptide Y signalling on hippocampal stem cells in health and disease. Mol Cell Endocrinol 2008; 288:52–62.

13. Malva JO, Xapelli S, Baptista S, Valero J, Agasse F, Ferreira R, Silva AP: Multifaces of neuropeptide Y in the brain-neuroprotection, neurogenesis and neuroinflammation. Neuropeptides 2012;46:299–308.

14. Decressac M, Barker RA: Neuropeptide Y and its role in CNS disease and repair. Exp Neurol 2012;2:38:265–272.

15. Zoccali C: Neuropeptide Y as a far-reaching neuromediator: from energy balance and cardiovascular regulation to central integration of weight and bone mass control mechanisms. Implications for human diseases. Curr Opin Nephrol Hypertens 2005;14:25–32.

16. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macá J, Carreras J, Soler J, Torres F, Campistol JM, Martínez-Castelao A; ESHOL Study Group: High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24:487–497.

17. Jeffries HJ, Virk B, Schiller B, Moran J, McIntyre CW: Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol 2011; 6:1326–1332.

18. Wahl HG, Graf S, Renz H, Fassbinder W: Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004;50:1071–1074.

19. Laveborn E, Lindmark K, Skagerlind M, Stegmayr B: NT-proBNP and troponin T levels differ after haemodialysis with a low versus high flux membrane. Kidney Int 2011; 81:359–365.

20. Kumar S, Khosravi M, Massart A, Davenport A: Is there a role for NT-pro-B-type natriuretic peptide in determining volume status in haemodialysis patients? Nephron Clin Pract 2012;12:32–37.

21. Sivalingam M, Suresh M, Farrington K: Comparison of B-type natriuretic peptide and NT-proBNP as predictors of survival in patients on high-flux hemodialysis and hemodiafiltration. Hemodial Int 2011; 15:359–365.

22. Mostovaya JM, Bots ML, van den Dorpel MA, Grooteman MP, Kamp O, Levesque R, Ter Wee PM, Nubé MJ, Blankestijn PJ: A randomized trial of hemodiafiltration and change in cardiovascular parameters. Clin J Am Soc Nephrol 2014;9:520–526.

23. Voroneanu L, Siripol D, Nistor I, Apetrii M, Hogas S, Onofriescu M, Covic A: Superior predictive value for NTproBNP compared with high sensitivity cTnT in dialysis patients: a pilot prospective observational study. Kidney Blood Press Res 2014;39:636–647.

24. Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazaric AH, den Hoedt CH, van der Tweel I, Levesque R, Nubé MJ, ter Wee PM, Blankestijn PJ; CONTRAST Investigators: Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012;23:1087–1096.